Baxter International Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Baxter International Inc. on November 30, 2021, covering events occurring on November 29, 2021. The filing primarily addresses the appointment of a new senior executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and corporate governance changes.
Material Changes
On November 29, 2021, the Company appointed Giuseppe Accogli as Executive Vice President and Chief Operating Officer, effective immediately. Mr. Accogli previously served as Senior Vice President and President of the Americas and Global Business Units. This appointment is accompanied by a revised offer letter detailing significant changes to his compensation structure.
Management Commentary and Compensation Details
Under the revised Offer Letter, Mr. Accogli's compensation package includes the following terms:
- Base Salary: $875,000 annually, effective immediately.
- Short-Term Incentive: Eligibility for the Management Incentive Compensation Program with a target of 95% of base salary, effective January 1, 2022.
- Long-Term Incentive (LTI): Eligibility to participate in the LTI Program for senior management beginning in March 2022, with a target grant value of $4,000,000.
- One-Time Grant: A one-time performance share unit (PSU) grant with a target value of $2,500,000 to be received in March 2022, subject to performance metrics and vesting schedules consistent with the 2022 annual LTI grant.
The filing notes that Mr. Accogli has served as a director of AdvaMed since September 2019 and has held various leadership roles within Baxter since joining in 2007.
Investor Verification Checklist
- Verify the full text of the Offer Letter (Exhibit 10.1) for specific performance metrics and vesting conditions attached to the $6.5 million in equity awards.
- Confirm the effective dates for the base salary increase and incentive program eligibility.
- Review the Company's proxy statement or subsequent filings for any impact on executive compensation peer group analysis or total shareholder return targets.
- Check for any related party transaction disclosures if Mr. Accogli holds other positions with entities doing business with Baxter.